Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2019

Al-Kawaaz M, Sanchez T, Kluk MJ. Evaluation of S1PR1, pSTAT3, S1PR2, FOXP1 Expression in Aggressive, Mature B Cell Lymphomas. J Hematop. 2019;12(2):57-65.

Mancuso CJ, Magro CM, Lipner SR. Acquired digital fibrokeratoma presenting as a painless nodule on the right fifth fingernail. Cutis. 2019;103(6):340-342.

Toyoda Y, Franck P, Brownstone ND, Lieberman M, Magro CM, Otterburn DM. Apocrine adenocarcinoma in the setting of apocrine hidrocystoma of the leg. Dermatol Online J. 2019;25(6).

Magruder M, Sholi AN, Gong C, Zhang L, Edusei E, Huang J, et al. Gut uropathogen abundance is a risk factor for development of bacteriuria and urinary tract infection. Nat Commun. 2019;10(1):5521.

Gaudino MF, Lorusso R, Ohmes LB, Narula N, McIntire P, Gargiulo A, et al. Open radial artery harvesting better preserves endothelial function compared to the endoscopic approach. Interact Cardiovasc Thorac Surg. 2019;29(4):561-567.

Acosta-Gonzalez G, Ouseph M, Lombardo K, Lu S, Glickman J, Resnick MB. Immune environment in serrated lesions of the colon: intraepithelial lymphocyte density, PD-1, and PD-L1 expression correlate with serrated neoplasia pathway progression. Hum Pathol. 2019;83:115-123.

Naccache SN, Callan K, Burnham CA, Wallace MA, Westblade LF, Bard JD. Evaluation of Oxacillin and Cefoxitin Disk Diffusion and Microbroth Dilution Methods for Detecting -Mediated β-Lactam Resistance in Contemporary Staphylococcus epidermidis Isolates. J Clin Microbiol. 2019;57(12).

Zhang Y, Zhou CK, Rencsok EM, Fall K, Lotan TL, Loda M, et al. A Prospective Study of Intraprostatic Inflammation, Focal Atrophy, and Progression to Lethal Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2019;28(12):2047-2054.

Khani F, Wobker SE, Hicks JL, Robinson BD, Barbieri CE, De Marzo AM, et al. Intraductal carcinoma of the prostate in the absence of high-grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations. J Pathol. 2019;249(1):79-89.

Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, et al. A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. Clin Cancer Res. 2019;25(1):43-51.